Candel Therapeutics (NASDAQ:CADL) Issues Quarterly Earnings Results, Misses Estimates By $0.17 EPS

Candel Therapeutics (NASDAQ:CADL - Get Free Report) issued its earnings results on Thursday. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.17), Zacks reports.

Candel Therapeutics Trading Up 0.9 %

NASDAQ:CADL traded up $0.08 on Monday, reaching $8.83. The stock had a trading volume of 725,950 shares, compared to its average volume of 2,657,232. The company has a 50-day moving average of $8.21 and a 200 day moving average of $6.95. The stock has a market cap of $286.76 million, a P/E ratio of -5.10 and a beta of -1.29. Candel Therapeutics has a 12-month low of $1.34 and a 12-month high of $14.60.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Bank of America started coverage on shares of Candel Therapeutics in a research report on Friday, February 7th. They issued a "buy" rating and a $15.00 price objective for the company. Citigroup assumed coverage on Candel Therapeutics in a research report on Thursday, February 20th. They issued a "buy" rating and a $25.00 price objective on the stock. Canaccord Genuity Group raised their target price on Candel Therapeutics from $20.00 to $25.00 and gave the company a "buy" rating in a report on Wednesday, February 26th. Finally, HC Wainwright reissued a "buy" rating and set a $19.00 price target on shares of Candel Therapeutics in a research report on Friday.

Remove Ads

Insider Buying and Selling

In related news, insider Francesca Barone sold 13,534 shares of the company's stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $7.22, for a total value of $97,715.48. Following the sale, the insider now directly owns 110,673 shares of the company's stock, valued at $799,059.06. This represents a 10.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CTO Seshu Tyagarajan sold 14,322 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $7.22, for a total transaction of $103,404.84. Following the transaction, the chief technology officer now owns 96,790 shares in the company, valued at $698,823.80. This trade represents a 12.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 41,529 shares of company stock worth $313,512. 41.60% of the stock is currently owned by corporate insiders.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.